Corcept Therapeutics Inc. Files Definitive Proxy Statement

TL;DR

<b>Corcept Therapeutics Inc. filed its Definitive Proxy Statement on April 10, 2024, detailing executive compensation and equity awards.</b>

AI Summary

CORCEPT THERAPEUTICS INC (CORT) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Corcept Therapeutics Inc. filed a Definitive Proxy Statement (DEF 14A) on April 10, 2024. The filing covers the period ending April 10, 2024. The company's fiscal year ends on December 31. Corcept Therapeutics Inc. is classified under Pharmaceutical Preparations (SIC 2834). The filing includes details on equity awards granted to executive officers and non-executive members for the years 2020-2023.

Why It Matters

For investors and stakeholders tracking CORCEPT THERAPEUTICS INC, this filing contains several important signals. This DEF 14A filing provides shareholders with crucial information regarding executive compensation, equity awards, and other governance matters, enabling informed voting decisions. Understanding the details of equity awards granted to both executive and non-executive personnel is important for assessing management's alignment with shareholder interests and the company's long-term incentive structure.

Risk Assessment

Risk Level: low — CORCEPT THERAPEUTICS INC shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and governance, with no immediate red flags.

Analyst Insight

Review the executive compensation details and equity award grants to understand management's incentives and potential impact on future performance.

Key Numbers

• 2024-04-10 — Filing Date (DEF 14A filing date)
• 2024-04-10 — Period of Report (Conformed period of report)
• 1231 — Fiscal Year End (Company's fiscal year end)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)

Key Players & Entities

• CORCEPT THERAPEUTICS INC (company) — Filer name
• CORT (company) — Ticker symbol
• DEF 14A (filing) — Form type
• 2024-04-10 (date) — Filing date
• 0001628280-24-015633 (filing) — Accession number
• 0001088856 (company) — Central Index Key
• 2834 (industry) — Standard Industrial Classification
• 149 COMMONWEALTH DRIVE (address) — Business address

FAQ

Industry Context

Corcept Therapeutics Inc. operates in the Pharmaceutical Preparations industry, focusing on the development and commercialization of therapies for severe metabolic, endocrine, and oncologic diseases.

Regulatory Implications

The filing is a DEF 14A, which is a standard SEC filing required for public companies to provide shareholders with information before their annual meeting, particularly concerning executive compensation and voting matters.

What Investors Should Do

1. Analyze the detailed breakdown of equity awards granted to PEO and Non-PEO members for the years 2020-2023.
2. Examine any disclosed adjustments or exclusions related to option and stock awards.
3. Review the filing for any specific proposals or resolutions being presented to shareholders for a vote.

Key Dates

• 2024-04-10: DEF 14A Filing — Definitive Proxy Statement filed by Corcept Therapeutics Inc.

Year-Over-Year Comparison

This filing is a DEF 14A, which is a routine disclosure and does not represent a change from previous filings in terms of its nature, but provides updated information on executive compensation and equity awards for the relevant periods.

Key Financial Figures

• $37,000 — ments, which are not expected to exceed $37,000. In addition to solicitation by mail, o

Filing Documents

• cort-20240410.htm (DEF 14A) — 1123KB
• cort-20240410_g1.jpg (GRAPHIC) — 135KB
• cort-20240410_g2.jpg (GRAPHIC) — 104KB
• cort-20240410_g3.jpg (GRAPHIC) — 103KB
• cort-20240410_g4.jpg (GRAPHIC) — 179KB
• cort-20240410_g5.jpg (GRAPHIC) — 201KB
• 0001628280-24-015633.txt (&nbsp;) — 3683KB
• cort-20240410.xsd (EX-101.SCH) — 3KB
• cort-20240410_def.xml (EX-101.DEF) — 5KB
• cort-20240410_lab.xml (EX-101.LAB) — 6KB
• cort-20240410_pre.xml (EX-101.PRE) — 4KB
• cort-20240410_htm.xml (XML) — 163KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 14 CODE OF ETHICS 14 PROHIBITION OF EMPLOYEE, OFFICER AND DIRECTOR HEDGING 14 DELINQUENT SECTION 16(A) REPORTS 14

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 15 EQUITY COMPENSATION PLAN INFORMATION 29 DIRECTOR COMPENSATION 29 COMPENSATION COMMITTEE REPORT 31 REPORT OF THE AUDIT COMMITTEE 32 FEES OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 33 PROPOSALS TO BE ACTED UPON AT THE 2024 ANNUAL MEETING 34 OTHER MATTERS 44 STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING 45 AVAILABLE INFORMATION 46 APPENDIX A A-1 Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park, California 94025 650-327-3270 PROXY STATEMENT 2024 ANNUAL MEETING OF STOCKHOLDERS General We are furnishing this proxy statement and the enclosed proxy in connection with the solicitation of proxies by our Board of Directors (the "Board") for use at the Annual Meeting of Stockholders of Corcept Therapeutics Incorporated (the "Company" or "Corcept") to be held on Friday, May 17, 2024 at 7:30 a.m. local time, at 149 Commonwealth Drive, Menlo Park, California 94025 and at any adjournments thereof (the "2024 Annual Meeting"). This proxy statement and accompanying proxy card are being first mailed to stockholders on or about April 15, 2024. Who Can Vote Only holders of our common stock at the close of business on April 5, 2024 (the "Record Date") are entitled to vote at the 2024 Annual Meeting. If a bank, broker or other intermediary is the record holder of your stock on the Record Date, that is, your shares are held in "street name," you must obtain and submit a legal proxy from your broker or other intermediary as the record holder, if you wish to attend the meeting in-person and vote your shares at that time. Shares Outstanding and Quorum As of the Record Date, there were 103,837,166 shares of our common stock outstanding. A majority of the outstanding shares of our common stock entitled to vote at the 2024 Annual Meeting must be present in person or by proxy, in order for there to be a quorum at the meeting. If a quorum is not present at the meeting, the chairman of the meetin

: Gender Identity

Part I: Gender Identity Directors 2 7

: Demographic Background

Part II: Demographic Background White 2 6 Native American — 1 LGBTQ+ 2 The Corporate Governance and Nominating Committee also ensures that a majority of the directors are independent under the rules of the Nasdaq Stock Market, that the Audit Committee and Compensation Committee are composed of independent directors, and that members of the Audit Committee possess the accounting and financial expertise the Nasdaq Stock Market and SEC rules require. Process for Identifying and Evaluating Nominees . With the assistance of other members of the Board, Corcept's management and in some cases third-party search firms, the Corporate Governance and Nominating Committee identifies candidates who have the desired qualities and skills. The Corporate Governance and Nominating Committee will also consider recommendations for nominees by stockholders. The Corporate Governance and Nominating Committee reviews biographical information and qualifications and checks the candidate's references. Qualified candidates are interviewed by at least one member of the Corporate Governance and Nominating Committee. Advancing candidates meet, either in person or by telephone, with all members of the Corporate Governance and Nominating Committee and as many other members of the Board as practicable. Candidates, whether recommended by the Corporate Governance and Nominating Committee or by stockholders, are presented to the Board for review and either (i) possible approval by the Board to fill a vacancy or (ii) nomination for a vote at the next meeting of stockholders. Stockholder Proposals for Nominees . The Corporate Governance and Nominating Committee will consider written proposals from stockholders for nominees for director. Such nominations should be submitted to the Secretary of our Company and should include the following information: (a) all information required by Regulation 14A of the Securities Exchange Act of 1934, as amended ("Exchange Act"), including such person's written c

View Full Filing

View this DEF 14A filing on SEC EDGAR